30 closest matches · ranked by relevance
Primary Bile Acid Diarrhea
Primary: Number of Patients Reported With Adverse Events , Serious Adverse Events and Death. — 9; 14; 0; 4 count of participants
Primary Bile Acid Malabsorption · Secondary Bile Acid Malabsorption · Chronic Diarrhoea
Primary: Changes in Fasting FGF19 — 71; 25; 130 percentage increase of baseline — p=0.007
Chronic Diarrhea · Irritable Bowel Syndrome With Diarrhea · Bile Acid Malabsorption
Primary: Fasting Serum C4 Levels — 2.2; 50.4 ng/ML
Chronic Diarrhea · Irritable Bowel Syndrome With Diarrhea · Bile Acid Malabsorption
Primary: Total Fecal Bile Acid (BA) Excretion — 10.7; 3.6 μmoles/g — p=0.001
Irritable Bowel Syndrome With Diarrhea
Primary: Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score Over 4 Weeks of Treatment Period — 5.89; 5.34; -1.25; -1.09 score on a scale
Type 2 Diabetes Mellitus · Obese · Overweight
Primary: Change in Postprandial Glucose — -2803; 629 mmol/6hr — p=<0.05
Diarrhea
Primary: Percent of Patients With Return Toward a Normal Fecal Bile Acid Pattern — 100 percentage of participants
Infantile Refsum's Disease · Zellweger Syndrome · Adrenoleukodystrophy
Primary: Number of Participants With Excretion of Atypical Bile Acids in Urine by Category — 10; 51; 11; 9 Participants
Gastroesophageal Reflux Disease
Primary: Protection Against DNA Damage by UDCA — 1.068; .82 Relative Densitometry Units
Bile Acid Malabsorption · Cholelithiasis
Primary: Change in Stimulated Fibroblast Growth Factor 19 (FGF19) From Baseline Before Versus Post Cholecystectomy — 81; 186 pg per mL — p=0.03
Diarrhea Predominant Irritable Bowel Syndrome
Primary: Change in Total 48 Hour Fecal Bile Acids (BA) From Baseline in Response to Treatment With Colesevelam — 1662; 3496 uM — p=0.012
Primary Biliary Cirrhosis
Primary: Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 8 — -26.06; -33.38; -41.42 percentage change from baseline — p== 0.2242
Irritable Bowel Syndrome
Primary: Changes in GIS Scores Between Baseline and After a 12 Week Intervention With Mesalamine or Placebo — 2.72; 2.22 units on a scale — p=.001
Constipation-predominant Irritable Bowel Syndrome
Primary: Colonic Geometric Center at 24 Hours (GC24) — 3.1; 3.5; 2.2 units on a scale
Functional Constipation
Primary: Colonic Transit at 24 Hours — 2.68; 3.12; 1.93 units on a scale — p=0.059
Bile Acid Synthesis Defect · Inborn Error of Bile Acid Metabolism · Inborn Error of Bile Acid Conjugation
Primary: Conjugated Cholic Acid (GCA) for the Treatment of Inborn Errors in Bile Acid Synthesis Involving Side-chain Conjugation. — 5 Participants
Progressive Multiple Sclerosis
Primary: Number of Participants With at Least One Treatment-related Adverse Event — 10; 7 Participants
Irritable Bowel Syndrome With Diarrhea
Primary: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With…
Obesity
Primary: Change in 48h-fecal Bile Acid Excretion (μmol/L) Between Baseline and High Fat Diet — 543; 344 (μmol/L)/48 hour
Irritable Bowel Syndrome With Diarrhea
Primary: Weekly Response for Abdominal Pain Intensity AND Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks). — 35.7; 34.7…
Bile Acid Synthesis Defect
Primary: Change in Atypical Urinary Bile Acid Excretion by FAB-MS (Fast-Atom-Bombardment Ionization-Mass Spectrometry) — 25; 6; 10; 10 Participants
Irritable Bowel Syndrome
Primary: Change in Mean Daily Abdominal Pain — 5.2; 5.3; 3.9; 3.8 score on a scale — p=0.78
Obesity · Healthy
Primary: Glucagon-Like Peptide-1 (GLP-1) — 18; 17 Participants
Primary Biliary Cirrhosis
Primary: Change in Serum Alkaline Phosphatase Levels. — -57.3 U/L — p=0.001
Primary Biliary Cirrhosis
Primary: DB Phase: Composite Endpoint Alkaline Phosphatase (ALP) And Total Bilirubin, 10 mg OCA Versus Placebo — 47; 10 percentage of participants — p=<0.0001
Primary Biliary Cirrhosis
Primary: Biochemical Response — 1 Participants
Primary Sclerosing Cholangitis · Biliary Atresia
Primary: Determine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary Atresia — 10; 0; 0; 0 participants
Primary Biliary Cholangitis
Primary: Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 3…
Primary Biliary Cholangitis
Primary: Percentage of Participants With Response Criteria for the Composite Endpoint of ALP <1.67 × Upper Limit of Normal (ULN), ≥15% Reduction in ALP, and Total Bilirubin ≤…
Primary Sclerosing Cholangitis
Primary: Count of Participants With Elevated Alanine Aminotransferase (ALT) at Baseline and With Clinically Significant Improvement at Month 3 — 10; 6 Participants